Theophylline Acetaldehyde as the Initial Product in Doxophylline Metabolism in Human Liver^S

Xiaohua Zhao, Hong Ma, Qiusha Pan, Haiyi Wang, Xingkai Qian, Peifang Song, Liwei Zou, Mingqing Mao, Shuyue Xia, Guangbo Ge, and Ling Yang

Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China (X.Z., Q.P., H.W., X.Q., P.S., L.Z., G.G., L.Y.); Center for Systems Pharmacokinetics, Shanghai University of Traditional Chinese Medicine, Shanghai, China (X.Z., Q.P., H.W., X.Q., P.S., L.Z., G.G., L.Y.); College of Basic Medical Sciences, Dalian Medical University, Liaoning, China (H.M.); Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China (H.M.); and Respiratory Medicine Department, Central Hospital Affiliated to Shenyang Medical College, Liaoning, China (M.M., S.X.)

Received October 8, 2019; accepted January 30, 2020

ABSTRACT

Doxophylline (DOXO) and theophylline are widely used as bronchodilators for treating asthma and chronic obstructive pulmonary disease, and DOXO has a better safety profile than theophylline. How DOXO's metabolism and disposition affect its antiasthmatic efficacy and safety remains to be explored. In this study, the metabolites of DOXO were characterized. A total of nine metabolites of DOXO were identified *in vitro* using liver microsomes from human and four other animal species. Among them, six metabolites were reported for the first time. The top three metabolites were theophylline acetaldehyde (M1), theophylline-7-acetic acid (M2), and etophylline (M4). A comparative analysis of DOXO metabolism in human using liver microsomes, S9 fraction, and plasma samples demonstrated the following: 1) The metabolism of DOXO began with a cytochrome P450 (P450)-mediated, rate-limiting step at the C ring

and produced M1, the most abundant metabolite in human liver microsomes. However, in human plasma, the M1 production was rather low. 2) M1 was further converted to M2 and M4, the end products of DOXO metabolism *in vivo*, by non-P450 dismutase in the cytosol. This dismutation process also relied on the ratio of NADP⁺/NADPH in the cell. These findings for the first time elucidated the metabolic sites and routes of DOXO metabolism in human.

SIGNIFICANCE STATEMENT

We systematically characterized doxophylline metabolism using *in vitro* and *in vivo* assays. Our findings evolved the understandings of metabolic sites and pathways for methylxanthine derivatives with the aldehyde functional group.

Introduction

Doxophylline (DOXO), theophylline (TP), aminophylline (Spina and Page, 2017), etophylline (ETO) (Sharma and Sharma, 1979), and caffeine (CA) are methylxanthine derivatives, and the first four compounds have been approved for use in clinical practice. Among them, TP and DOXO are clinically more effective and widely used in the treatment of asthma and chronic obstructive pulmonary disease. A recent meta-analysis of 696 patients with asthma shows that DOXO has slightly better efficacy and a much better profile of safety than TP (Rogliani et al., 2019); hence it has a broader therapeutic window in treating asthma. DOXO also shows fewer side effects on cardiac function (Dini and Cogo, 2001), sleep rhythm (Sacco et al., 1995), gastric secretions

(Lazzaroni et al., 1990), and the central nervous system (Cravanzola et al., 1989), and it exhibits lower risks of drug-drug interaction (Mennini et al., 2017). In February 2014, the US Food and Drug Administration granted an orphan drug designation to DOXO for treating bronchiectasis (<https://www.accessdata.fda.gov/scripts/opdlisting/ood/detailedIndex.cfm?cfgridkey=399413>). Efforts have been made to understand the mechanism underlying the superior safety profile of DOXO. Studies show that DOXO exhibits rather weak effects on the well characterized *in vivo* targets of TP, such as phosphodiesterase and adenosine receptors (van Mastbergen et al., 2012). This evidence is insufficient to justify the equivalent efficacy and better safety of DOXO in clinical usage. Therefore, the molecular mechanism of DOXO still remains to be investigated.

The metabolic stability of a compound is determined by its structure. TP, CA, and DOXO share identical parental skeleton, and differ only in the N-7 substituent groups. We assigned A, B, and C rings to the structures of DOXO to accurately describe the metabolic sites and derivative functional groups (Fig. 1).

TP lacks a substituent group at the N-7 position and has the lowest *in vivo* metabolic rate among the three drugs. The primary metabolic

This work was supported by the National Key Research and Development Program of China [2017YFC1702000, 2017YFC1700200], National Science Foundation (NSF) of China [81773810, 81922070, 81973393], and the Key Science and Technology Program of Shenyang supported by Shenyang Science and Technology Bureau [17-230-9-05].

<https://doi.org/10.1124/dmd.119.089565>.

^SThis article has supplemental material available at dmd.aspetjournals.org.

ABBREVIATIONS: 1-ABT, 1-aminobenzotriazole; AUC, area under the plasma concentration–time curve; CA, caffeine; CyLM, monkey liver microsome; DOXO, doxophylline; ETO, etophylline; HET, 2'-hydroxyethyl ester theophylline acetic acid; HLM, human liver microsome; HLS9, human liver S9; HPLC, high-performance LC; LC, liquid chromatography; MLM, mouse liver microsome; MS/MS, tandem mass spectrometry; P450, cytochrome P450; RaLM, rabbit liver microsome; RLM, rat liver microsome; TA, theophylline-7-acetaldehyde; TAA, theophylline-7-acetic acid; TOF, time of flight; TP, theophylline.

Fig. 1. Schematic diagram of skeleton of methylxanthine derivatives.

pathways of TP are demethylation at the N-1 and N-3 positions (Fig. 1). The area under the plasma concentration–time curve (AUC) of TP accounts for about 91% of the total AUC in human plasma after oral TP administration (Rodopoulos and Norman, 1997). Therefore, the widely observed fluctuation of TP concentration in the blood among different individuals (Bertil, 2010) is mainly attributed to other factors, rather than the instable structure of the compound. One possible cause is that TP has a large variation in apparent volume of distribution (Tanikawa et al., 1999) and strong tissue binding activity (Shum and Jusko, 1987). Once binding competition occurs (Tröger and Meyer, 1995), plasma concentration of TP could be highly volatile, leading to side effects such as cardiac and neurotoxicity (Minton and Henry, 1996).

CA has a methyl group at the N-7 position, and the overall demethylation activity increases. In human, CA metabolized to paraxanthine (84%), theobromine (12%), and TP (4%). These three metabolites could be further demethylated (Nehlig, 2018). The AUC of parent drug CA in human plasma accounts for 56% of the total AUC (Martínez-López et al., 2014). It is worth noting that CA metabolite profiles exhibit significant variation between individuals. The demethylation of CA and TP is primarily catalyzed by CYP1A (Fort et al., 1996). Several studies show distinct differences in the metabolic capacity of CYP1A among individuals (Dai et al., 2017, 2015). It has been recently demonstrated that CYP2E1 also participates in CA metabolism, which would further contribute to the metabolic variation of CA (Nehlig, 2018). Therefore, the individual variation of CA concentration in human blood arises from both the structural instability and the variation of metabolic enzyme activity.

DOXO has a 1,3-dioxolane ring (cyclic acetal) at the N-7 position. Previous studies show that DOXO is relatively stable in rat liver microsomes (RLMs) as 95% of the parent compound has been recovered. The metabolites detected in RLMs are TP and 2'-hydroxyethyl ester theophylline acetic acid (HET) (Grosa et al., 1986). However, these two products are not present in human serum. Clinical pharmacology studies of oral and intravenously administered DOXO show distinct individual variation of absorption, distribution, metabolism, and excretion profiles for DOXO (Shukla et al., 2009). The biologic instability of DOXO in vivo is characterized by quick elimination and short half-life. The only metabolite detected in the human blood is the inactivated ETO. Therefore, DOXO has been proposed as the active compound rather than the prodrug responsible for its clinical efficacy and safety (Matera et al., 2017).

Our recent study also demonstrated that DOXO was instable in human. We identified theophylline-7-acetic acid (TAA) to be a new product of DOXO metabolism in vivo in addition to ETO, and the AUC of intact DOXO in plasma after intravenous drip was only 27% (Fang et al., 2019). Taken together, the published studies on DOXO metabolism focus on the pharmacokinetics of prototype compound, whereas in vitro evidence on biochemical stability and drug metabolism of DOXO is limited. In this study, we performed a systematic investigation and comparative analysis on DOXO metabolism using human liver microsomes, human liver S9, and human blood serum. We

identified and characterized the metabolites of DOXO and illustrated the interconversion relationships in vitro and in vivo.

Materials and Methods

Chemicals and Reagents. DOXO (99.7%), TP (99.5%), and ETO (99.7%) were purchased from Dalian Meilunbio. Co., Ltd. (Dalian, China). Theophylline-7-acetaldehyde (TA; 91.4%) was bought from Beijing Comparison Pharmaceutical Tech. Co., Ltd. (Beijing, China). TAA (99.7%) was from Aladdin Industrial Corporation (Shanghai, China). D-glucose 6-phosphate, glucose-6-phosphate dehydrogenase, β -NADP⁺, NADPH, uridine 5'-diphosphoglucuronic acid trisodium salt, polyethylene glycol hexadecyl ether, and 1-aminobenzotriazole (1-ABT) were obtained from Sigma-Aldrich (St. Louis, MO). HET (92.7%) was synthesized by Guoliang Chen at Shenyang Pharmaceutical University (Shenyang, China). All other reagents were either liquid chromatography (LC) grade or the highest grade commercially available.

Enzyme Sources. Pooled liver microsomes from human (HLMs), mouse (MLMs), rabbit (RaLMs), rat (RLMs), and monkey (CyLMs) and pooled human liver S9 (HLS9) were purchased from Research Institute for Liver Diseases (Shanghai) Co. Ltd. (Shanghai, China) and stored at -80°C .

In Vitro Incubation Reaction. The total volume of each incubation was 200 μL , and organic solvent did not exceed 2 μL .

For phase I metabolism, incubation was performed in PBS buffer (0.1 M, pH = 7.4). The incubation system contained liver microsomes/HLS9 (0.5 mg/ml), DOXO/TA/TAA/ETO/HTE (100 μM) and NADPH-regenerating system including glucose-6-phosphate dehydrogenase (1 U/ml), MgCl_2 (5 mM), D-glucose 6-phosphate (10 mM), and β -NADP⁺ (1 mM). After preincubation for 5 minutes, the reaction was initiated by adding β -NADP⁺. The mixtures incubated 60 minutes at 37°C on a thermo-shaker. To inhibit the cytochrome P450 (P450) activity in phase I metabolism, 1-ABT (500 μM) was preincubated with HLMs/HLS9 and NADPH-generating system for 20 minutes at 37°C ; then DOXO was added.

For phase II metabolism, the incubation system contained 50 mM Tris-HCl (pH 7.4), HLMs (0.5 mg/ml), DOXO/TAA/ETO (100 μM), uridine 5'-diphosphoglucuronic acid (2 mM), MgCl_2 (5 mM), and polyethylene glycol hexadecyl ether (0.1 mg/mg protein).

For kinetics analysis, the incubation system contained PBS (0.1 M, pH 7.4), HLS9 (0.1 mg/ml), TA (1–500 μM), and β -NADP⁺/freshly prepared NADPH (1 mM). The reaction was initiated by adding HLS9, and the incubation time was 6 minutes.

For chemical stability test, 100 μM DOXO was incubated in 0.2% formic acid at 37°C for 60 minutes.

All these reactions were terminated by adding 100 μL ice-cold acetonitrile and then centrifuged at 20,000g for 20 minutes at 4°C . Incubation systems without liver microsomes/HLS9, cofactor, or substrate were used as controls.

Ethics Approval and Human Subjects. This research was approved by the Independent Ethics Committee in 2018, January (approval 2018 [00021]). Human subjects enrolled in this project were informed about the purpose, procedure, and risk of the study. Three volunteers were female, Asian, and aged 25, 25, and 26 years. Physical examinations were performed before the enrollment, and no pathologic conditions were found.

Protocol for Drug Administration and Blood Sampling. Under fasting conditions, 100 mg DOXO was administered as single dose by intravenous drip for 30 minutes. Blood samples were collected from the contralateral antecubital vein at predose and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 4.5, 6.5, 8.5, 10.5, 12.5, and 24.5 hour after the intravenous administration started. Plasma was immediately separated from the blood by centrifugation at 4450g for 10 minutes at 4°C and stored at -20°C .

Sample Preparation for Mass Spectrometry Analysis. For in vitro samples, 3 μL of the supernatant was used for LC-Triple time-of-flight (TOF) analysis. The supernatant was diluted with 0.2% formic acid (v: v = 1:2), and 1 μL was used for LC–tandem mass spectrometry (MS/MS) analysis. For plasma preparation, 25 μL sample was deproteinized with 75 μL acetonitrile. The mixture was diluted with 100 μL water containing 0.2% formic acid. After centrifugation for 20 minutes at 20,000g, 5 μL of the supernatant was used for LC-Triple TOF and 2 μL for LC-MS/MS.

LC-Triple TOF Analyses. Metabolite identification was performed on a 5600+ Triple TOF quadrupole–time-of-flight mass spectrometer equipped

with a DuoSpray source (Sciex). The mass spectrometer was coupled with an ExionLC system. Chromatographic separation was performed on an Acquity ultraperformance LC BEH C18 column (3.0 × 100 mm i.d., 1.7 μm; Waters). A 15-minute gradient with water containing 0.2% formic acid (A) and acetonitrile containing 0.2% formic acid (B) was used at a flow rate of 0.3 ml/min. Injection volume was 3 μl for all samples. Autosampler and column oven temperatures were maintained at 4°C and 50°C, respectively. Ionization was operated using an electrospray ionization source. Data were collected in the positive ion mode with Analyst TF software version 1.7.1 (Sciex). The mass spectrometer was conducted in full-scan TOF–mass spectrometry (m/z 100–1000) combined with information-dependent acquisition MS/MS modes; the collision energy was set as 15 ± 10 eV. Both ion source gases 1 and 2 were set to 50 psi. Curtain gas was set to 35 psi. The ion spray voltage floating was 5500 V, and the temperature was 550°C.

LC-MS/MS Analysis. Metabolite detection was performed on a 4500 QTRAP mass spectrometer (triple quadrupole-linear ion trap) equipped with a TurboV ion source (Sciex). The mass spectrometer was coupled with an LC-20ADXR high-performance LC (HPLC) system (Shimadzu). DOXO and its metabolites were separated on a ultraperformance LC BEH C18 (2.1 × 50 mm i.d., 1.7 μm; Waters) analytical column. The mobile phase was flowing at 0.35 ml/min and composed of water containing 0.2% formic acid (A) and acetonitrile (B). The gradient elution mode was applied. Data were acquired and processed with Analyst software version 1.6.3 (Sciex). Detection of the ions were operated in the positive multiple-reaction monitoring mode. The ion transitions for analytes were monitored and are summarized in Supplemental Table 1. Ion source gases 1 and 2 were set to 55 and 60 psi, respectively. The temperature and ion spray voltage floating were 550°C and 5500 V, respectively. Curtain gas was at 40 psi. Collision gas was set at medium. The collision energy and declustering potential for all compounds were 27 and 65 eV. The multiple-reaction monitoring chromatograms for metabolic products in HLMs, HLS9, human plasma, and blank control under the above conditions are shown in Supplemental Fig. 1.

Results

LC-Triple TOF Analyses of DOXO and Metabolites. To identify the unknown metabolites, we first used LC-Triple TOF to investigate the chromatographic behavior, characteristic ions, and mass fragmentation pattern of DOXO. In the positive ion mode, DOXO was eluted at 6.7 minutes (Supplemental Fig. 2A) with a protonated molecular ion at m/z 267.1085. The MS/MS (MS^2) spectrum of DOXO exhibited major fragment ions at m/z 223.0814, 210.0867, 181.0712, 166.0602, 138.0654, and 124.0494 (Supplemental Fig. 2B). The tentative MS^2 fragmentation pattern and identification of fragment ions were displayed in Supplemental Fig. 2C. The fragment ion at m/z 223.0814 was formed via the cleavage of two C–O bonds on the 1,3-dioxolane ring. The ion at m/z 210.0867 was generated by the loss of tertiary amides from the A ring. The ions at m/z 181.0712 and 124.0494 were the structurally diagnostic ions of TP. The ion at m/z 138.0654 was produced by the loss of 1,3-dioxolane ring from the fragment ion at m/z 210.0867. The m/z 166.0602 ion was formed by the loss of tertiary amides from the ion at m/z 223.0814.

Then we characterized the metabolites of DOXO in the HLM incubation system. A total of nine metabolites were detected, and six of them, M1, M2, M6, M7, M8, and M9, were reported for the first time. The preliminary structures of these metabolites were examined. Among them, M1 was the most abundant metabolite. Six of these nine metabolites were derived from the metabolism of the C ring, including M1 (TA), M2 (TAA), M3 (TP), M4 (ETO), M5 (HET), and M9 (DOXO dehydrogenation product) (Supplemental Fig. 3), and their structures were confirmed by standard references. The other three metabolites, M6, M7, and M8, were derived from metabolism on the A and B rings and were analyzed by ion fragment pattern to predict the structures and metabolic sites (Supplemental Fig. 3). No glucuronide conjugate was detected in phase II metabolism in HLMs (Supplemental Fig. 8).

M1 was eluted at 5.1 minutes, and its protonated molecular ion was at m/z 223.0828 with elemental composition $C_9H_{10}N_4O_3$. The ion at m/z

241.0935 was the hydrated protonated ion of M1. The ions at m/z 124.0499 and 181.0720 suggested that the A and B rings remained unchanged, and the ions at m/z 138.0660 and 195.0875 implied that the B ring was linked with a methyl group. Based on these observations, we hypothesized M1 to be TA. It was verified by a comparing of the chromatography and mass spectra between M1 and the reference standard of TA. The MS^2 spectrum and the speculated molecular structure of M1 are shown in Supplemental Fig. 3A.

M2 was eluted at 4.65 minutes and the elemental composition was $C_9H_{10}N_4O_4$. Compared with DOXO, M2 was short of a C_2H_4 . The precursor ion at m/z 239.0772 and its dehydration ion at m/z 221.0653 indicated that there was a hydroxyl group in M2. The ions at m/z 124.0495, 138.0640, and 181.0708 suggested the presence of unmodified A and B rings. Thus, the dealkylation occurred on the 1,3-dioxolane ring and M2 was identified to be TAA (Supplemental Fig. 3B). It was further confirmed by a comparison with the TAA reference standard.

M3 was eluted at 4.67 minutes and exhibited a molecular ion peak at m/z 181.0714. The elemental composition of metabolite M3 was $C_7H_8N_4O_2$, identical to that of TP. The characteristic fragment ion was at m/z 124.0502. By comparing the chromatographic and mass spectrometry behavior between M3 and the reference standard, we confirmed M3 to be TP (Supplemental Fig. 3C).

M4 was eluted at 5.24 minutes and showed a protonated molecular ion at m/z 225.0969 with elemental composition of $C_9H_{12}N_4O_3$, which suggested the loss of a C_2H_2O from the parent drug DOXO. The dehydration ion at m/z 207.0872 indicated the presence of a hydroxyl group in M4. The ions at m/z 124.0490 and 181.0713 implied that the metabolic reactions occurred on the 1,3-dioxolane ring. Therefore, M4 was proposed to be ETO, and it was confirmed by a comparison with the reference standard (Supplemental Fig. 3D).

M5 was eluted at 5.58 minutes with protonated molecular ion at m/z 283.1033. The elemental composition of M5 was $C_{11}H_{14}N_4O_5$, suggesting that it was monohydroxylated product of DOXO. M5 shared the same fragment ions with M2 at m/z 124.0502, 181.0711, 193.0712, 221.0656, and 239.0769 (Supplemental Fig. 3E), indicating that the two compounds had similar chemical structure segment. The ion at m/z 265.0192 was a dehydrated ion. These observations collectively suggested that an oxygen atom was introduced into the 1,3-dioxolane ring, followed by a ring-opening reaction and dehydrogenation. In addition, a previous study showed that HET was the major metabolite of DOXO in RLMs (Grosa et al., 1986). Taken together, we proposed M5 to be HET, and it was confirmed by comparison with the chemically synthesized reference standard.

M9 showed a $[M + H]^+$ ion at m/z 265.0923 with the elemental composition of $C_{11}H_{12}N_4O_4$. It was eluted at 6.36 minutes as a dehydrogenation product of DOXO. The presence of fragment ion at m/z 181.0710 indicated that the structure of the A and B rings remained intact and the dehydrogenation reaction occurred on the C ring (Supplemental Fig. 3F).

M6 was eluted at 5.84 minutes with the same elemental composition as M5 ($C_{11}H_{14}N_4O_5$). Unlike M5, the MS/MS spectrum of M6 had the fragment ion at m/z 197.0662 rather than 181.0711 (Supplemental Fig. 3G), suggesting that the oxygen was introduced to the A or B ring via a hydroxylation step. Considering the structural characteristics of the A and B rings and the metabolic sites of TP (Rodopoulos and Norman, 1997), this hydroxylation might occur at the C-8 position. This was also supported by the fact that no dehydration peak was found in M6. Of note, the peak area of M6 was less than 5% of the peak area of M5.

M7 and M8 had the same element composition of $C_{10}H_{12}N_4O_4$ and were eluted at 5.18 and 5.72 minutes, respectively. They possessed the same protonated molecular ions at m/z 253.092, which were 14 Da lower

than DOXO, indicating that M7 and M8 were demethylated products of DOXO (Supplemental Fig. 3H). The presence of the ion at m/z 167.0558 but not 181.0712 suggested that demethylation occurred at the N-1 or N-3 positions of the A ring. However, it was difficult to determine which demethylation product was dominant. In addition, the peak area of M7 was less than 5% of the peak area of M8.

The details for each metabolite, including retention time, accurate mass, molecular formula, and fragmented ions are shown in Supplemental Table 2. Reference standards of DOXO and the major metabolites, M1, M2, M4, and M5, were examined by HPLC, and the purity was quantified by peak area normalization method. The HPLC conditions and the chromatogram results are shown in Supplemental Fig. 4 and Supplemental Table 3. The structures of these reference standards were characterized by high-resolution mass spectrometry and NMR. The MS² spectra and NMR data are shown in Supplemental Figs. 5–7.

Chemical Stability of DOXO. We examined the chemical stability of DOXO and found that less than 0.1% DOXO was destroyed after a 60-minute incubation at 37°C in 0.2% formic acid, and little M1 formation was detected under this condition. Thus, DOXO was chemically stable. The biochemical stability of DOXO was tested in following experiments.

Metabolism of DOXO in Liver Microsomes. To better understand the mechanism of *in vitro* DOXO metabolism, we compared the metabolite profiles in liver microsomes among five different species. The nine metabolites identified in HLMs were also present in liver microsomes of mouse, rabbit, rat, and monkey, and no additional novel metabolites were detected.

The metabolic rates of DOXO in different species was determined by LC-MS/MS. The formations of the four major metabolites, M1, M2, M4, and M5, were quantified. Due to the incomplete structure information and lack of reference standard compounds, the trace metabolites M8 and M9 were semiquantitatively analyzed based on the calibration curve of M4. The typical calibration curves are shown in Supplemental Table 4. The abundance of M3, M6, and M7 was extremely low in HLMs; thus no further quantitative measurement was conducted. The metabolic rate was calculated based on the production of metabolites per milligram of protein per minute within a 2-hour incubation. The total rate of six metabolites for CyLMs, RLMs, RaLMs, MLMs, and HLMs was 888, 635, 555, 313, and 222 pmol, respectively (Fig. 2).

Among the five species, the total metabolic conversion rate of DOXO was the lowest in HLMs and the highest in CyLMs. Based on the characteristic metabolite profile of each species, defined by the relative abundance of individual metabolite, the liver microsomal metabolism of the five species could be classified into two categories (Fig. 2). Type I was defined by one predominant metabolite, M1, including HLMs (87% M1) and RLMs (88% M1). The only difference between HLMs and RLMs was that the amount of M5 in RLMs was significantly higher than that in HLMs. Type II was defined by the presence of two major metabolites, M1 and M4, including MLMs (64% M1, 26% M4), CyLMs (28% M1, 57% M4), and RaLMs (31% M1, 62% M4). Of note, M1 was dominant in MLMs, whereas M4 was dominant in CyLMs and RaLMs. What was in common between Type I and Type II metabolism was that all the major metabolites were mainly derived from the metabolism of the C ring, rather than the A or B ring.

Metabolism of DOXO in Human Plasma. Three healthy volunteers were intravenously dripped with 100 mg DOXO for 30 minutes, and the plasma samples were collected and analyzed by LC-MS/MS. Four metabolites, M1, M2, M4, and M5, were quantitatively measured, whereas M8 and M9 were subjected to semiquantitative examination. The results showed that M2 and M4 were the most abundant metabolites in plasma. The major *in vitro* product M1 in HLMs was present at rather

Fig. 2. Main metabolites of DOXO in liver microsomes of different species (HLMs, MLMs, RaLMs, RLMs, and CyLMs). Results are shown as means ($n = 3$).

low abundance in plasma. M5, M8, and M9 were also present at trace amount. The plasma concentration–time curve for each metabolite is shown in Fig. 3.

Then we compared the concentration–time curves between DOXO and its key metabolites M1, M2, and M4 (Fig. 3). The parent drug DOXO was quickly eliminated after intravenous drip, and the elimination rate was about 50 l/h. The T_{max} for M1 and M2 was at 0.5 and 0.75 hours in all three volunteers; the T_{max} for M4 was at 1, 1.5, and 2 hours, respectively, in the three volunteers. The sequence of the peak times for these three major metabolites indicated that M1 and M2 might be the initial or intermediate products in DOXO metabolism.

Identification of Initial Product in DOXO Metabolism. To investigate the differences between *in vitro* and *in vivo* DOXO metabolism, we used DOXO, M1, M2, M4, or M5 as individual substrate (100 μ M/each) and measured the formation of other compounds in HLMs and HLS9 (Fig. 4).

When DOXO was used as substrate (Fig. 4A), the total percentage of M1, M2, and M4 in final products was about 98% in both HLMs and HLS9, whereas the total amount of M5, M8, and M9 did not exceed 2%. In HLMs, M1 accounted for 87% of the total metabolic products, whereas in HLS9, the ratio of M1 dropped to 26%. In contrast, M2 and M4 together accounted for 11% of the total metabolites in HLMs, and this ratio increased to 72% in HLS9, which was closely aligned with the *in vivo* data. These results indicated that the enzymes responsible for M2 and M4 formation were more likely to be in cytosol. Furthermore, when a broad-spectrum P450 inhibitor (1-ABT) was added to the HLMs and HLS9 incubation systems, the production of M1, M2, and M4 was significantly reduced in both settings, suggesting that the formation of M2 and M4 was still dependent on the liver microsomal system. Based on these results, we proposed that DOXO was metabolized to M1 by P450 enzymes and that M1 was further metabolized to M2 and M4 in cytosol. 1-ABT inhibited P450 activity to prevent the M1 formation, hence indirectly reducing the formation of M2 and M4.

To validate this speculation, we used standard references of M1, M2, M4, M5, the key metabolites produced in HLMs, as substrates to investigate the continuous metabolism in HLS9.

When M1 was used as the substrate (Fig. 4B), only M2 and M4 were detected in both HLMs and HLS9, confirming that M2 and M4 were products of M1 metabolism. Of note, similar amounts of M2 (derived from M1 oxidation) and M4 (derived from M1 reduction) were produced. The total amount of M2 and M4 in HLS9 was about 8-fold of that in HLMs, further demonstrating that the cytosol enzymes were

Fig. 3. Drug concentration–time curve of prototype and metabolites of DOXO after intravenous drip of 100 mg DOXO in the plasma samples of three healthy human subjects (A–C).

required for the $M1 \rightarrow M2 + M4$ conversion. Although 1-ABT had little impact on the production of M4, it partially inhibited the metabolism of M2 and exerted a nonspecific inhibitory effect on M1 oxidation. Taken together, these results strongly suggested that DOXO can hardly be directly converted to M2 or M4 without being firstly converted to M1 and that the DOXO to M1 conversion was the rate-limiting step at the beginning of the metabolic reaction chain.

When M2 or M5 was used as substrate, no above known metabolites or DOXO were detected in HLMs or HLS9. When using M4 as the substrate, only trace amount of M1 was detected in HLMs and HLS9 (data not shown). These results indicated that M2, M4, and M5 cannot interconvert with each other. More evidence is needed to validate that M2 and M4 were derived from M1.

Enzymatic Kinetics. Since M1 is aldehyde, M2 is acid and M4 is alcohol, the $M1 \rightarrow M2 + M4$ conversion is a dismutase-mediated reaction. To examine the effects of cofactors on this reaction, we characterized the enzymatic kinetics with the presence of either $NADP^+$ or NADPH (Fig. 5). In the HLS9 system (0.1 mg/ml), the final

concentration of M1 was within the range of 1–500 μ M. When only $NADP^+$ was added, after 6-minute incubation, the oxidation product M2 and reduction product M4 were present, and M2 production was much higher than M4; when NADPH was added, a totally opposite reaction

Fig. 4. Metabolism of DOXO and major metabolite M1 in HLMs and HLS9. Results are shown as means ($n = 2$). (A) The effects of P450 broad-spectrum inhibitor 1-ABT and NADPH-regenerating system on DOXO metabolism in HLM/HLS9 incubation system and on DOXO metabolism with the presence of NADPH-regenerating system only. (B) The effects of P450 broad-spectrum inhibitor 1-ABT and NADPH-regenerating system on M1 metabolism in HLM/HLS9 incubation system and on M1 metabolism with the presence of NADPH-regenerating system only. Incubation procedures followed standard operating procedures for phase I metabolism in vitro incubation.

pattern was observed, and the formation of M4 was much more than M2. The four kinetic curves associated with different cofactors and products all displayed non-Michaelis-Menten features. The $V_{\max}$ (picomoles per minute per milligram protein) and K_{half} (μM) were calculated for these four kinetics curves (Fig. 5): $V_{\max} = 2.23$, $K_{\text{half}} = 20.5$ (NADP^+ , M2), $V_{\max} = 2.92$, $K_{\text{half}} = 729.8$ (NADP^+ , M4) (Fig. 5, A–C), $V_{\max} = 0.53$, $K_{\text{half}} = 52.7$ (NADPH , M2), $V_{\max} = 5.53$, $K_{\text{half}} = 362.5$ (NADPH , M4) (Fig. 5, D–F). These results suggested that multiple enzymes were involved in both the oxidation and reduction processes.

Taken together, our data suggested that DOXO was firstly catalyzed by one or more microsomal P450 enzymes to produce M1, and M1 was subsequently dismutated to M2 and M4 by cytosolic enzymes with the presence of $\text{NADP}^+/\text{NADPH}$. The conversion relationship between DOXO and its major metabolites is shown in Fig. 6.

Discussion

Drug metabolism research primarily focuses on the following: 1) The structure-metabolism relationship, which usually requires the comparison of a series of compounds sharing the same parental structure to map the characteristic metabolic sites and patterns mediated by a particular enzyme. 2) The sequential metabolic reactions in a metabolic pathway. Starting with a single compound, the metabolism is often composed of a series of metabolic conversions, which might involve multiple enzymes and different metabolic routes and produce a set of metabolites in sequence. Among the three methylxanthine derivatives, DOXO is featured by its distinct metabolic sites and pathways compared with CA and TP; hence it could be considered a model compound for drug metabolism study.

The current understanding of the metabolic sites for methylxanthine derivatives is primarily from the research of CA and TP metabolism (Nehlig, 2018). CA metabolism remains one of the earliest models to illustrate the sequential metabolism of methylxanthine derivatives in vivo (McKeague et al., 2016). CA is characterized by three methyl groups at the N-1, N-3, and N-7 positions on the methylxanthine skeleton (A and B rings), and the N-3 site is the most labile. Demethylation on each of these three sites produces paraxanthine, theobromine, or TP, and further demethylation could still happen on the rest of the methyl sites. Compared with TP, CA carries a methyl group on the N-7 position, which increases the lability of the N-3 site of the A ring. DOXO is featured by the cyclic acetal group (C ring) on the N-7 position, and previous studies have not explored how this substituent group affects the metabolic sites and activity of this compound. Our results demonstrated that the C ring of DOXO largely changed the key metabolic sites. The metabolism of DOXO predominantly happened on the C ring and produced the six major metabolites of the nine. The other three minor metabolites were derived from demethylation on the A and B rings. In addition, the results of the chemical stability of DOXO showed that M1 formation detected in the incubation system was mediated by enzymatic catalysis. Based on these evidence, we conclude that the methyl groups on the N-1, N-3, and N-7 positions interact with each other to collectively determine the demethylation pattern of CA, and the cyclic acetal group on the N-7 position dominantly guides the characteristic opening of the C ring of DOXO. The lability of these three compounds is ranked from high to low: $\text{DOXO} > \text{CA} > \text{TP}$. The lability of DOXO arises from the C ring rather than the A and B rings. This is further supported by the detection of trace amount of M6, M7, and M8 in DOXO metabolism.

Previous studies on DOXO metabolism in human primarily focus on pharmacokinetics in vivo, and ETO has been identified as the major product (Matera et al., 2017). However, the understanding of the complete metabolic process, i.e., the DOXO to ETO conversion, is still

limited. It is suspected that DOXO might have been intentionally designed as a prodrug of ETO. However, there are no published data available regarding the design of DOXO compound based on our literature search. To fully investigate the DOXO metabolism, a systematic characterization of all metabolites and their conversion relationships using both in vivo and in vitro systems is required.

In our study, we first characterized the metabolite profiles of DOXO in human liver microsomes, human liver S9, and human blood serum. In HLMs, M1 was the predominant metabolite, whereas in human plasma, M2 and M4 were the major metabolites. In HLS9, the percentages of M1, M2, and M4 was 26%, 25%, and 47%, respectively. Therefore, there are two hypotheses for the sequential metabolism of M1 (TA), M2 (TAA), and M4 (ETO): 1) oxidation: M4 (alcohol) is oxidized to M1 (aldehyde), and M1 continues to be oxidized to M2 (acid); 2) dismutation: M1 (aldehyde) is simultaneously oxidized to M2 (acid) and reduced to M4 (alcohol). In the first scenario, M4 is the intermediate product of metabolism of DOXO, and it should be converted into M1 and M2 in the end. We used M4 as substrate in HLMs and HLS9 incubation and intragastric administered M4 in SD rat (data not shown). Only trace amount of M4 was reverted to M1, and there was no M2 signal at all. Therefore, M4 was concluded to be the stable end product in both in vivo and in vitro systems, which in turn rejected the first hypothesis. The second scenario is that M1 could be directly dismutated into M2 and M4. In HLS9 incubation, we took M1 as substrate and added NADPH-generating system (with a mixture of NADP^+ and NADPH) as cofactor. Results showed that M1 was converted to M2 and M4. In addition, we demonstrated that M2 and M4 were not interconvertible (Fig. 6). Therefore, M1 was validated as the initial metabolite in DOXO metabolism. Additional experiments were conducted to verify that without the formation of the initial metabolite, M1, DOXO can hardly be directly metabolized to M2 and M4. We further demonstrated that in HLMs and HLS9, the initial metabolism of DOXO was blocked by the broad-spectrum P450 inhibitor. These data collectively confirmed the second hypothesis. Moreover, the metabolic rate for the DOXO to M1 conversion in HLMs was 222 pmol/mg per minute, whereas the rate for the $\text{M1} \rightarrow \text{M2} + \text{M4}$ conversion in HLS9 was about 2000 pmol/mg per minute. HLMs is known to be concentrated by nearly 3-fold via centrifugation of HLS9 (Hakooz et al., 2006); therefore, the metabolic enzymes converting M1 to M2 and M4 are present in non-HLM fractions of HLS9. The metabolic rate for the $\text{M1} \rightarrow \text{M2} + \text{M4}$ conversion was roughly 30-fold of that for the DOXO to M1 conversion. Taken together, we concluded that the conversion from DOXO to M1 conversion is the rate-limiting step in DOXO metabolism.

In addition, we also set up HLM-mediated reactions in UDP-glucuronosyltransferase incubation system, using DOXO, M2, and M4 as individual substrate, and we did not find any glucuronidation (Supplemental Fig. 8).

Aldehyde dismutation is a classic reaction, either spontaneous or catalyzed by dismutase. Our data validated that the dismutation of M1 was enzyme dependent, and it primarily happened in HLS9 with the presence of cofactors (Fig. 4B). Several aldehyde oxidases and reductases might have been involved in this process (Ahmed Laskar and Younus, 2019). The preliminary experiment on HLS9 kinetics showed that both oxidized (NADP^+) and reduced (NADPH) cofactors could facilitate this dismutation reaction (Fig. 5). The difference was that the presence of oxidized cofactor NADP^+ majorly led to oxidation product M2, whereas the reduced cofactor NADPH mostly led to reduction product M4. An Eadie-Hofstee plot was used to display the kinetic curves: two curves for the oxidation product M2 shared the similar pattern, although the cofactors were contrasted between these two reactions. The same trend was observed for the other two curves for the reduction product M4 (Fig. 5). All these reactions exhibited the non-

Fig. 5. The enzyme kinetics analysis and Eadie-Hofstee plot of M1 dismutation to M2 and M4 in HLS9 with the presence of either NADP⁺ or NADPH. (A) The enzyme kinetic curve of M1 reacting with NADP⁺ in HLS9. (B and C) The Eadie-Hofstee plots of M2 (B) and M4 (C) reacting with NADP⁺. (D) The enzyme kinetic curve of M1 reacting with NADPH in HLS9. (E and F) The Eadie-Hofstee plots of M2 (E) and M4 (F) reacting with NADPH.

Michaelis-Menten feature, suggesting that multiple enzymes were involved in this dismutation process.

To summarize, in human liver cells, the initiation of DOXO metabolism relies on the microsomal enzymes, especially P450 and NADPH. Under pathologic conditions, as NADPH decreases, the initiation of DOXO metabolism, i.e., the formation of M1, could significantly slow down. Whether M1 stays stable or is metabolized to M2 and M4 is determined by the presence of dismutase and the ratio of NADP⁺/NADPH in the cytosol (Fig. 5). All these factors could

contribute to the pharmacokinetic variability of DOXO among individuals and among different health conditions (Shukla et al., 2009).

In conclusion, in this study we used in vitro and in vivo assay to identify and characterize the initial steps and key metabolites in DOXO metabolism. We systematically investigated the conversion relationships between DOXO and the abundant metabolites M1, M2, and M4. Our results showed that DOXO was firstly metabolized to M1 by P450 enzymes in liver microsomes and that M1 was subsequently converted to M2 and M4 by the dismutase in the cytosol. These findings laid the

Fig. 6. Schematics of the relationship between the interconversion of DOXO and its main metabolites. No known metabolites or DOXO were detected when M2 or M5 was used as a substrate at 100 μM. SER, smooth endoplasmic reticulum. An arrow with a dashed line represents metabolic conversion rate < 0.1%; an arrow with a solid line represents metabolic conversion rate between 0.1% and 1%; a white arrow represents metabolic conversion rate between 1% and 10%; a gray arrow represents metabolic conversion rate > 20%.

ground for future studies to elucidate the metabolic pathways of DOXO and the structure-metabolism relationships for methylxanthine derivatives.

Acknowledgments

We thank Dr. Guoliang Chen for the help in synthesis and purification of reference standards (M5) and Dr. Jiangwei Zhang for the support in mass spectrometry analysis. We also acknowledge Dr. Hailing Cheng and Dr. Pixu Liu for manuscript writing and revision.

Authorship Contributions

Participated in research design: Zhao, Ma, Xia, Yang.

Conducted experiments: Zhao, Ma, Pan, Mao.

Contributed new reagents or analytic tools: Zhao, Pan, Zou, Ge.

Performed data analysis: Zhao, Qian, Song, Zou.

Wrote or contributed to the writing of the manuscript: Zhao, Ma, Pan, Wang, Zou, Yang.

References

- Ahmed Laskar A and Younus H(2019) Aldehyde toxicity and metabolism: the role of aldehyde dehydrogenases in detoxification, drug resistance and carcinogenesis. *Drug Metab Rev* **51**: 42–64.
- Bertil BF(2010) *Methylxanthines*, Springer, Heidelberg, Dordrecht, London, New York.
- Cravanzola C, Reboani MC, Grosa G, and Franzone JS(1989) Doxofylline in rat brain in relation to locomotor activity. *Drug Metab Dispos* **17**:437–440.
- Dai ZR, Feng L, Jin Q, Cheng H, Li Y, Ning J, Yu Y, Ge GB, Cui JN, and Yang L(2017) A practical strategy to design and develop an isoform-specific fluorescent probe for a target enzyme: CYP1A1 as a case study. *Chem Sci (Camb)* **8**:2795–2803.
- Dai ZR, Ge GB, Feng L, Ning J, Hu LH, Jin Q, Wang DD, Lv X, Dou TY, Cui JN, et al.(2015) A highly selective ratiometric two-photon fluorescent probe for human cytochrome P450 1A. *J Am Chem Soc* **137**:14488–14495.
- Dini FL and Cogo R(2001) Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects. *Curr Med Res Opin* **16**:258–268.
- Fang LN, Mao MQ, Zhao XH, Yang L, Jia H, and Xia SY(2019) Development and validation of a UPLC-MS/MS method for quantification of doxofylline and its metabolites in human plasma. *J Pharm Biomed Anal* **174**:220–225.
- Fort DJ, Stover EL, Propst T, Hull MA, and Bantle JA(1996) Evaluation of the developmental toxicity of theophylline, dimethyluric acid, and methylxanthine metabolites using Xenopus. *Drug Chem Toxicol* **19**:267–278.
- Grosa G, Franzone JS, and Biglino G(1986) Metabolism of doxofylline by rat liver microsomes. *Drug Metab Dispos* **14**:267–270.
- Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, and Houston JB(2006) Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. *Pharm Res* **23**:533–539.
- Lazzaroni M, Grossi E, and Bianchi Porro G(1990) The effect of intravenous doxofylline or aminophylline on gastric secretion in duodenal ulcer patients. *Aliment Pharmacol Ther* **4**: 643–649.
- Martínez-López S, Sarriá B, Baeza G, Mateos R, and Bravo-Clemente L(2014) Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. *Food Res Int* **64**:125–133.
- Matera MG, Page C, and Cazzola M(2017) Doxofylline is not just another theophylline!. *Int J Chron Obstruct Pulmon Dis* **12**:3487–3493.
- McKeague M, Wang YH, Cravens A, Win MN, and Smolke CD(2016) Engineering a microbial platform for de novo biosynthesis of diverse methylxanthines. *Metab Eng* **38**:191–203.
- Mennini FS, Sciatella P, Marcellusi A, Marcobelli A, Russo A, and Caputi AP(2017) Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxofylline vs. theophylline. *Expert Rev Pharmacoecon Outcomes Res* **17**:503–510.
- Minton NA and Henry JA(1996) Acute and chronic human toxicity of theophylline. *Hum Exp Toxicol* **15**:471–481.
- Nehlig A(2018) Interindividual differences in caffeine metabolism and factors driving caffeine consumption. *Pharmacol Rev* **70**:384–411.
- Rodopoulos N and Norman A(1997) Elimination of theophylline metabolites in healthy adults. *Scand J Clin Lab Invest* **57**:233–240.
- Rogliani P, Calzetta L, Ora J, Cazzola M, and Matera MG(2019) Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. *Multidiscip Respir Med* **14**:25.
- Sacco C, Braghiroli A, Grossi E, and Donner CF(1995) The effects of doxofylline versus theophylline on sleep architecture in COPD patients. *Monaldi Arch Chest Dis* **50**:98–103.
- Sharma PL and Sharma RM(1979) Comparative bioavailability of sustained-release and conventional tablets of hydroxyethyltheophylline in man. *Int J Clin Pharmacol Biopharm* **17**:394–396.
- Shukla D, Chakraborty S, Singh S, and Mishra B(2009) Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. *Expert Opin Pharmacother* **10**:2343–2356.
- Shum LY and Jusko WJ(1987) Theophylline tissue partitioning and volume of distribution in normal and dietary-induced obese rats. *Biopharm Drug Dispos* **8**:353–364.
- Spina D and Page CP(2017) Xanthines and phosphodiesterase inhibitors. *Handb Exp Pharmacol* **237**:63–91.
- Tanikawa K, Matsumoto Y, Matsuzaki T, Matsumoto M, Fukuoka M, Noguchi S, and Goshima T(1999) Population pharmacokinetic analysis of theophylline: relationship between serum concentrations and clinical effects in therapeutic drug monitoring. *Yakugaku Zasshi* **119**: 861–867.
- Tröger U and Meyer FP(1995) Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation. *Clin Pharmacokinet* **28**:287–314.
- van Mastbergen J, Jolas T, Allegra L, and Page CP(2012) The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism. *Pulm Pharmacol Ther* **25**:55–61.

Address correspondence to: Ling Yang, Institute of Interdisciplinary Integrative Medicine Research, and Center for Systems Pharmacokinetics, Shanghai University of Traditional Chinese Medicine, No. 1200, Cailun Road, Shanghai 201203, China. E-mail: yling@shutcm.edu.cn